Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Sales | 303,745 | 300,091 | 279,896 | 300,131 | 236,736 |
| Cost of Goods | 50,006 | 64,147 | 50,738 | 51,617 | 43,118 |
| Gross Profit | 253,739 | 235,944 | 229,158 | 248,514 | 193,618 |
| Operating Expenses | 273,953 | 325,712 | 289,981 | 821,937 | 274,653 |
| Operating Income | -20,208 | -89,621 | -60,085 | -572,806 | -80,917 |
| Interest Expense | 10,119 | 9,732 | 9,980 | 9,944 | 9,843 |
| Other Income | 6,021 | 7,187 | 3,252 | -195 | 1,634 |
| Pre-tax Income | -24,306 | -92,166 | -66,813 | -582,945 | -89,126 |
| Income Tax | -8,016 | -1,446 | -29,388 | -163,931 | -6,075 |
| Net Income Continuous | -16,290 | -90,720 | -37,425 | -419,014 | -83,051 |
| Net Income | $-16,290 | $-90,720 | $-37,425 | $-419,014 | $-83,051 |
| EPS Basic Total Ops | -0.09 | -0.49 | -0.22 | -2.58 | -0.51 |
| EPS Basic Continuous Ops | -0.09 | -0.48 | -0.22 | -2.58 | -0.51 |
| EPS Diluted Total Ops | -0.09 | -0.50 | -0.22 | -2.58 | -0.51 |
| EPS Diluted Continuous Ops | -0.09 | -0.48 | -0.22 | -2.58 | -0.51 |
| EBITDA(a) | $-136 | $-68,895 | $-30,518 | $-543,922 | $-61,882 |